Webseiten-Bericht für vbc.ac.at

vbc.ac.at

Webseiten-Bericht für vbc.ac.at

 Generiert am 20 Februar 2026 19:49 PM

Aktuelle Statistiken? UPDATE !

Der Wert ist 63/100

SEO Inhalte

Die Inhaltsanalyse zeigt, ob Seitentitel, Beschreibungen, Überschriften, Bilder und Textstruktur Suchmaschinen und Besuchern klare Signale geben.

Seitentitel

Vienna BioCenter | Life Science Excellence at the heart of Europe

Länge : 65

Der Seitentitel von vbc.ac.at ist mit 65 Zeichen gut dimensioniert und liegt im empfohlenen Bereich von 10 bis 70 Zeichen. Damit bekommen Suchmaschinen und Besucher schon in der Ergebnisliste einen klaren ersten Hinweis auf den Inhalt.

Seitenbeschreibung

Vienna BioCenter offers a unique combination of research, education and companies. Find out about our campus, our jobs and more!

Länge : 130

Für vbc.ac.at ist eine passende Meta-Beschreibung vorhanden: 130 Zeichen bieten genug Raum für den Inhalt der Seite, ohne den empfohlenen Rahmen von 70 bis 160 Zeichen zu sprengen.

Suchbegriffe

Bei vbc.ac.at wurden keine Meta-Suchbegriffe gefunden. Das ist für moderne Suchmaschinen nicht kritisch, dennoch kann eine saubere interne Themenliste helfen, den Inhalt bewusster zu strukturieren. Bei Bedarf können Sie dieses kostenlose Werkzeug verwenden.

Og META Eigenschaften

Die OG-Meta-Daten von vbc.ac.at sind vorhanden. Das verbessert die technische Grundlage für geteilte Links, weil Vorschauen nicht allein automatisch erraten werden müssen.

Eigenschaft Inhalt
title Vienna Bio Center
description Work at one of Europe's hotspots for life sciences!
image https://www.viennabiocenter.org/fileadmin/user_upload/VBC/Homepage/Carousel_train.jpg
image:url https://www.viennabiocenter.org/fileadmin/user_upload/VBC/Homepage/Carousel_train.jpg
image:width 1600
image:height 510
type website
url https://www.viennabiocenter.org/

Überschriften

H1 H2 H3 H4 H5 H6
0 19 607 0 0 0
  • [H2] Vienna BioCenter - Top Life Science Cluster
  • [H2] Facts and Figures
  • [H2] Education and Career
  • [H2] Seven Research Institutions
  • [H2] Key Discoveries
  • [H2] HUMAN BRAIN ORGANOIDS
  • [H2] HUMAN BRAIN ORGANOIDS
  • [H2] CRISPR/Cas9
  • [H2] CRISPR/Cas9
  • [H2] MECHANISMS OF CHROMOSOME SEGREGATION
  • [H2] MECHANISMS OF CHROMOSOME SEGREGATION
  • [H2] EPIGENETICS
  • [H2] EPIGENETICS
  • [H2] 1001 GENOMES
  • [H2] 1001 GENOMES
  • [H2] Key Events
  • [H2] News
  • [H2]
  • [H2] Cookies
  • [H3] Catching viruses in the act of sabotage
  • [H3] How cells import their waste disposal machine into the nucleus
  • [H3] Axolotl muscle stem cells cater to different regeneration strategies
  • [H3] License to kill
  • [H3] Studying immune cell fate inside the body of mice with CRISPR
  • [H3] A cellular strategy for building protein-making machines
  • [H3] Neurobiology meets RNA processing
  • [H3] From one complex to many: Rethinking the BLOC/BORC system
  • [H3] Seeing proteins fold as they are being made
  • [H3] Nell Saunders receives EMBO Fellowship
  • [H3] FWF Special Research Program ‘Meiosis‘ extended
  • [H3] How Genetic Grammar Shapes Antibody Evolution
  • [H3] Jovana Jovanovic secures this year’s 14th PhD Fellowship for the Perutz
  • [H3] ERC Consolidator Grant for Clemens Plaschka
  • [H3] Broken DNA’s missing match: how cohesin guides DNA repair
  • [H3] Boosting Protein Research with New Mass Spectrometry Technology
  • [H3] Unable to unwind, but not unhealthy
  • [H3] Twice the labs, twice the cake: A shared PhD journey at the Vienna BioCenter
  • [H3] Manuel Matzinger awarded APMA Society Medal for single-cell proteomics research
  • [H3] The secret of safe reproduction
  • [H3] The beginning of the end: Vienna BioCenter collaboration reveals how PIWI proteins protect animal genomes
  • [H3] Unnatural selection
  • [H3] A new start for mitophagy
  • [H3] Making diagnostics simpler, cheaper and open-source
  • [H3] FWF Principal Investigator Project Grant for Daniel Grabarczyk
  • [H3] EMBO fellowship for Guilherme Bastos-Ventura
  • [H3] Celebrating 20 years of transformative basic research at the Perutz
  • [H3] Cut to fit
  • [H3] Clemens Plaschka elected EMBO member
  • [H3] How do human antibodies get better at fighting infections?
  • [H3] Recognizing research talent: Max Perutz PhD fellows 2025
  • [H3] Releasing the brakes on the immune system: how a precision trick might help fight tumours
  • [H3] Victoria Deneke receives International Zebrafish Society award
  • [H3] Flying in the face of conventional wisdom
  • [H3] A kinase goes into the recycling business
  • [H3] Edvinas Stankunas named Medical University of Vienna Researcher of the Month
  • [H3] A not so futile cycle?
  • [H3] BIF fellowship for Sachin Mishra and Max Graf
  • [H3] How cells decide on the life or death of a protein
  • [H3] FWF ESPRIT Postdoc fellowship for Virginia Busetto
  • [H3] HFSP fellowship for Ida Jentoft
  • [H3] This is not a phosphatase
  • [H3] Emmanuelle Charpentier awarded Honorary Doctorate by the University of Vienna
  • [H3] Location, location, location
  • [H3] Georg Winter announced as AITHYRA’s deputy director for biomedicine
  • [H3] Thomas Juffmann is appointed to Full Professor
  • [H3] Leopoldina honors Elly Tanaka with Schleiden Medal
  • [H3] Daniel Gerlich receives Erwin Schrödinger Award
  • [H3] Illuminating brain circuits in the axolotl
  • [H3] Duckweed differentially marks old and new transposons
  • [H3] Kristina Stapornwongkul to start research group at IMBA
  • [H3] First snapshot of retrotransposon in action
  • [H3] AITHYRA institute starts operations at Marxbox
  • [H3] John Kendrew Award for Irma Querques
  • [H3] Monoclonal Antibody facility – validated, specific and sensitive detection tools
  • [H3] Perutz group leader Sebastian Falk earns tenure
  • [H3] Anais Elewaut wins Egon Macher Award
  • [H3] FakET: new method advances electron microscopy with AI simulations
  • [H3] Sven Klumpe to start cryo-Electron Tomography lab at IMP and IMBA
  • [H3] Taming inflammation by licensed elimination of mRNAs
  • [H3] Tenure for two Perutz group leaders
  • [H3] ERC Proof of Concept grant for Jonas Ries
  • [H3] Unprecedented protein quantification in single cells using advanced proteomics
  • [H3] In the right place, at the right time
  • [H3] Beyond loops: cohesin plays central role in linking DNA architecture and epigenetics
  • [H3] EJI Ita Askonas Prize for Anna Obenauf
  • [H3] Imaging on scales
  • [H3] EMBO fellowship Amena Nabih
  • [H3] BIF Fellowship for Tara McAteer
  • [H3] Lisa Appel and Johannes Benedum are Researchers of the Month at the Medical University of Vienna
  • [H3] Seipin: Guardian of Lipid Balance
  • [H3] FWF funding for Daniela Pollak and Franziska Lorbeer
  • [H3] Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®
  • [H3] More than the sum of its parts
  • [H3] A turning point for cancer treatment: monocytes boost T-cells in immunotherapy
  • [H3] Collaboration, computation, culture: Jacob Schreiber's year at the IMP
  • [H3] Mapping the genome’s off-switches
  • [H3] Elusive sensory organ: Pigeons detect magnetic fields through inner ear
  • [H3] Anais Elewaut wins 2025 Denise P. Barlow Award
  • [H3] One step back, two steps forward
  • [H3] ASAP: more Parkinson’s funding for the Martens lab
  • [H3] Austrian Decoration of Honour for Jan-Michael Peters
  • [H3] Jan-Michael Peters elected External Scientific Member of the Max Planck Institute of Biochemistry
  • [H3] Congratulations to the VBC PhD Awardees of 2024
  • [H3] Time for lunch
  • [H3] Controlling condensation by phosphorylation
  • [H3] Staying mobile
  • [H3] Beginning of life: molecular "lock-and-key" of fertilisation found
  • [H3] Anna Obenauf joins ADAPTMET to train the next generation of metastasis scientists
  • [H3] Teamwork makes the gene work: how enhancers collaborate to control gene expression
  • [H3] Rabitsch Award 2024 for Belén Pacheco-Fiallos
  • [H3] Belén Pacheco-Fiallos receives ÖGBMT Life Science PhD Award Austria
  • [H3] “Humans evolved to be storytellers”
  • [H3] Who let the FoxO in?
  • [H3] Disordered by design
  • [H3] Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate
  • [H3] Man is but a worm (with some small differences)
  • [H3] Vallee Scholarship for Perutz group leader Irma Querques
  • [H3] Expanding the chemical toolbox to study how the ribosome comes together
  • [H3] Targeted protein breakdown in mice reveals new insights into B-cell development
  • [H3] Nuclear pore basket - octopus-like arms unveiled
  • [H3] Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
  • [H3] BIF Fellowship for Paul Welzl
  • [H3] Keeping muscle cells fit: how one helper protein does the trick
  • [H3] Francisco Balzarotti wins 2024 Frontiers of Science Award
  • [H3] ORFtag: innovative method to tag and study proteins in cells
  • [H3] Two prestigious postdoc fellowships for Kevin Sabath
  • [H3] DOC Fellowship for David Hollaus
  • [H3] Two negatives make a positive
  • [H3] Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®
  • [H3] Clemens Plaschka receives 2024 Eppendorf Award
  • [H3] Finding needles in haystacks: The FACS facility
  • [H3] Unlocking the disassembly of a molecular editor
  • [H3] Damage control: Targeting mitochondria
  • [H3] You shall not pass
  • [H3] Survival of the filamentous
  • [H3] All Eyes on the Proteome
  • [H3] Unrecyclable: how protein aggregates evade clearance
  • [H3] Otto Hahn Medal and Award for Ida Jentoft
  • [H3] New Perutz Principal Investigator Projects funded by FWF
  • [H3] Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
  • [H3] Jacob Schreiber to join IMP faculty as visiting scientist
  • [H3] Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
  • [H3] Joris van der Veeken secures FWF funding
  • [H3] IMP Emeritus Director Barry Dickson elected Fellow of the Royal Society
  • [H3] Bernardo de Almeida wins 2024 Denise P. Barlow Award
  • [H3] Nature’s 3D Printer: Bristle Edition
  • [H3] Time is of the essence
  • [H3] Filip Nemcko among Forbes Slovakia “30 Under 30”
  • [H3] Revving up the engine: Immunity on Standby
  • [H3] HFSP grant for consortium led by Kristin Tessmar-Raible
  • [H3] Clemens Plaschka elected to ÖAW Young Academy
  • [H3] Perutz group leaders receive individual funding from FWF
  • [H3] Don’t judge a book by its cover
  • [H3] 5 ERC Grants Awarded to Vienna BioCenter Scientists
  • [H3] HFSP Fellowship for IMP postdoc Vytaute Boreikaite
  • [H3] Seeing the unseeable
  • [H3] FWF and ÖAW award “Disruptive Innovation Grant” to Johannes Schmoellerl (IMP)
  • [H3] Mass Spec-tacular: Proteomics at the Perutz
  • [H3] IMBA Welcomes Elly Tanaka as Scientific Director
  • [H3] FWF Emerging Fields grant for search of immunotherapy against childhood cancer
  • [H3] "Heart" of the spliceosome: putting together a molecular machine
  • [H3] Marie Skłodowska-Curie fellowship for Rupert Faraway to study mRNA selection mechanism
  • [H3] Three GMI scientists awarded Marie Skłodowska-Curie Postdoctoral Fellowships
  • [H3] Researchers at the Vienna BioCenter and in Ghana team up to advance diagnostics in Africa
  • [H3] Funding for two interdisciplinary projects to ‘understand biology with artificial intelligence’
  • [H3] Prestigious EMBO Fellowships for two IMP postdocs
  • [H3] Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
  • [H3] Sperm's creative approach to genome packing
  • [H3] What does cooking have to do with science? - Interview with new group leader Pim Huis in 't Veld
  • [H3] How eggs keep their messenger RNAs quiet
  • [H3] Decoding genome instability: New doc.funds initiative at the Perutz
  • [H3] Artificial Intelligence cracks code of gene regulation
  • [H3] New insights into how B cells time the duplication of their genome
  • [H3] Alejandro Burga (IMBA) and David Haselbach (IMP) join EMBO Young Investigator Program
  • [H3] The stage is yours, DIDO!
  • [H3] First multi-chamber heart organoids unravel human heart development and disease
  • [H3] Decoding cell fate: Key mechanism in stem cell switch identified
  • [H3] Nine “Highly Cited Researchers” at Vienna BioCenter in 2023
  • [H3] New Max Perutz PhD fellows
  • [H3] Phosphatase loss spells problems for the prostate
  • [H3] Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®
  • [H3] AVINA Grant for CeMESS group leader Shaul Pollak
  • [H3] Why TOFU is good for worms
  • [H3] The last stand - Plant stem cells put up a fight against viruses
  • [H3] International Birnstiel Award 2023 celebrates six outstanding scientists
  • [H3] Scientists show how cells build protein destruction signals
  • [H3] Immunologists reveal how the Pax5 protein regulates B cell development and commitment
  • [H3] CHOOSEn fate: one brain organoid’s tale on Autism
  • [H3] Goldilocks and the E3 ligase
  • [H3] Unearthing the hidden trove of long non-coding RNAs in plants
  • [H3] Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
  • [H3] Broadcasting DNA using transposons: ERC Starting Grant for Irma Querques
  • [H3] Network-based approaches open a new avenue to classify and treat rare diseases
  • [H3] Prestigious fellowships awarded to Max Perutz Labs PhD students
  • [H3] Lipid Chemistry Empowers Nuclear Shape
  • [H3] 2.5M euros funding for single-cell proteomics
  • [H3] 20th Vienna BioCenter PhD Symposium: 9/10 November 2023
  • [H3] "In science, you can’t get bored" - Interview with new group leader Irma Querques
  • [H3] A CRISPR-based lab tool for lineage tracing in vivo
  • [H3] HiCognition: A computational tool to navigate the genome in 3D
  • [H3] FWF awards ESPRIT grant to study single-cell proteomics of human blastoid
  • [H3] A cohesin-regulated tug-of-war inside chromosomes
  • [H3] IMP Senior Group Leader Anna Obenauf elected EMBO Member
  • [H3] Virus-like transposons wage war on the species barrier
  • [H3] How land plants regulate tissue development and organogenesis
  • [H3] START grant for Stephanie Ellis
  • [H3] Many roads lead to Rome
  • [H3] 3 new FWF grants awarded to Max Perutz Labs scientists
  • [H3] Dissecting the forces that govern epigenetic memory
  • [H3] IMP's Elly Tanaka elected to National Academy of Sciences
  • [H3] HFSP grant awarded to Kristina Djinovic and Jonas Ries
  • [H3] Elucidating the mechanism behind the medicine
  • [H3] Yasin Dagdas elected to the OeAW’s Young Academy
  • [H3] Muscle health depends on lipid synthesis
  • [H3] FWF approves Cluster of Excellence with CeMESS lead
  • [H3] Alfred Hauptmann Prize for research on Tuberous Sclerosis at IMBA
  • [H3] Traffic jam: gene transcription hampers cohesin’s travel along chromosomes
  • [H3] Win some – lose some: how cells adapt to aneuploidy
  • [H3] The dual face of photoreceptors during seed germination
  • [H3] Egon Macher Award for Lukas Leiendecker
  • [H3] Learning from viruses
  • [H3] Embryos gaining independence
  • [H3] Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate
  • [H3] Autophagy: The molecular regulation of self-eating
  • [H3] Do it yourself – kinase activation revisited
  • [H3] "Guardian of the Cell": structure and key function of giant protein explained
  • [H3] A tale of DNA loops: how distant DNA segments come together to make different types of antibodies
  • [H3] Stressing out the immune system
  • [H3] SNSF fellowship for postdoc Milica Vulin
  • [H3] Bryophytes branch differently… also at the molecular level
  • [H3] Switch it off: new insights into repressors of gene transcription
  • [H3] Coping with chromosomal stress
  • [H3] Portrait of a protein family
  • [H3] Weiss-Kruszka syndrome and the failure to establish neuronal identity
  • [H3] Punching holes in the nucleus
  • [H3] FWF awards doc.funds and stand alone project grants
  • [H3] Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate
  • [H3] Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate
  • [H3] Sebastian Falk joins EMBO Young Investigator program
  • [H3] Awakening the genome
  • [H3] ERC Starting Grants for Joanna Jachowicz and Kelly Swarts
  • [H3] Revealing the architectural secrets inside mini-organs
  • [H3] Max on the wall
  • [H3] Awards of the Vienna BioCenter PhD Symposium 2022
  • [H3] HUSHing repetitive-like elements contributes to normal brain development and function
  • [H3] FWF grants awarded to Max Perutz Labs scientists
  • [H3] New stop along the cellular journey of recycling organelles in plants
  • [H3] Old drugs new tricks
  • [H3] Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate at Leading Scientific Conferences
  • [H3] “Kipferl”: Guiding the defense against jumping genes
  • [H3] New light for electron microscopy
  • [H3] Circalunar clocks: using the right light
  • [H3] Breaking down proteins: How starving cancer cells switch food sources
  • [H3] Stephanie Ellis named a 2022 Vallee Scholar
  • [H3] Old drugs hint at new ways to beat chronic pain
  • [H3] Conversing with the past: how evolution shaped the human mind
  • [H3] Where art and science meet
  • [H3] When mothers shut down the fathers’ genes in the embryo
  • [H3] Transcription factor PAX5 linked to antibody deficiency and brain development
  • [H3] Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
  • [H3] How the genome is packed into chromosomes that can be faithfully moved during cell division
  • [H3] Receptor FIBCD1 newly identified in neuro-developmental disorders
  • [H3] AAAS Wachtel Cancer Research Award 2022 for Anna Obenauf (IMP)
  • [H3] On standby: how the developing embryo guards against viral infection
  • [H3] The axolotl, a new model to improve the healing of broken bones
  • [H3] The beginning of life: The early embryo is in the driver's seat
  • [H3] Johannes Zuber elected EMBO Member
  • [H3] CEBINA publishes data demonstrating the anti-histamine azelastine inhibits infection by major variants of SARS-CoV-2
  • [H3] “The idea is to connect people” - Manuela Baccarini elected Vice-Rector of the University of Vienna
  • [H3] Exhibition about Max Perutz draws over 5.000 visitors
  • [H3] “Cherish the beginning” - Interview with new group leader Stephanie Ellis
  • [H3] Climate@MaxPerutzLabs initiative wins Austrian Sustainability Award 2022
  • [H3] Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001
  • [H3] Anna Obenauf and Andrea Pauli promoted to Senior Scientists
  • [H3] Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
  • [H3] ÖAW DOC Fellowships awarded to Max Perutz Labs students
  • [H3] Tracking cells in the regenerating limb through space and time
  • [H3] BacPROTACs: antibiotics of the future
  • [H3] Putting a finger on meiosis
  • [H3] Milestone in understanding regulation of gene transcription
  • [H3] Rendezvous at night – how moonlight fine-tunes animal reproduction
  • [H3] Undergraduate student fits one more piece to the regeneration puzzle
  • [H3] ERC Proof of Concept to investigate clinical applications of blastoids
  • [H3] Anna Obenauf part of international consortium to study bone cancer
  • [H3] Diana Pinheiro to establish research group at IMP
  • [H3] An open-source COVID-19 test empowers African diagnostics and research
  • [H3] Austrian Science Fund supports heart regeneration research for next four years
  • [H3] EMA accepts filing of marketing authorization application for Valneva’s inactivated COVID-19 Vaccine Candidate
  • [H3] IMP Postdoc Paul Murphy joins the ESPRIT Programme
  • [H3] EMBO Fellowship for IMP postdoc Franziska Lorbeer
  • [H3] Harnessing artificial intelligence to predict and control gene regulation
  • [H3] Science for Resilience: Conference at Vienna BioCenter to discuss outlooks on Covid-19
  • [H3] Alwin Köhler elected corresponding member of the Austrian Academy of Sciences
  • [H3] City of Vienna Prize presented to Meinrad Busslinger and Jürgen Knoblich
  • [H3] IMP scientists solve first plant proteasome structure with supermarket spinach
  • [H3] #ScienceChatIMBA: Double agents - How stomach stem cells change allegiance upon injury
  • [H3] Austrian Academy of Sciences honours Elly Tanaka with full membership
  • [H3] Squid genome sheds light on extraordinary brain evolution
  • [H3] F.-Ulrich Hartl to give Max Birnstiel Lecture
  • [H3] DNA loop formation linked to Cornelia de Lange Syndrome
  • [H3] Scientists discover essential role of two proteins for fertilisation
  • [H3] Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
  • [H3] MSCA Postdoc Fellowship for Elias Adriaenssens
  • [H3] Valneva Receives Conditional Marketing Authorization from UK MHRA for its Inactivated COVID-19 Vaccine
  • [H3] New lessons from an old master
  • [H3] FWF Stand-Alone grants awarded to Max Perutz Labs scientists
  • [H3] Minister of Education, Science and Research visits Vienna BioCenter
  • [H3] ERC Consolidator Grants for Andrea Pauli and Yasin Dagdas
  • [H3] Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate
  • [H3] Max Perutz PhD Fellowships awarded
  • [H3] Cell fate determination: making sense out of nonsense
  • [H3] Ignaz Lieben Prize awarded to Kristin Tessmar-Raible
  • [H3] Resistance and tolerance: two sides of the same coin
  • [H3] Valneva Receives Emergency Use Authorization from Bahrain for its Inactivated COVID-19 Vaccine VLA2001
  • [H3] Valneva Receives Initial CHMP Assessment of its Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
  • [H3] Peter Schlögelhofer promoted to University Professor
  • [H3] Valneva Awarded Up to £20 Million by Scottish Enterprise to Advance Vaccine Development
  • [H3] Keeping meiotic entry in check
  • [H3] How a small RNA pathway talks to the heterochromatin machinery
  • [H3] Aiming for the basket
  • [H3] Moritz Gaidt to study innate immunology at IMP
  • [H3] ERC grant for Thomas Juffmann
  • [H3] Blooming too soon: timing is crucial to error-free cell division
  • [H3] Stay positive – how the brain incites mice to react positively to both fear and reward
  • [H3] Not all brains are equal: Why the human brain is more vulnerable to disease
  • [H3] Of inclusive science and exceptional mentoring: science communication award for Victoria Deneke
  • [H3] IMP students characterise a sperm protein essential for zebrafish fertilisation
  • [H3] New funding for meiosis research
  • [H3] Valneva’s Inactivated COVID-19 Vaccine Candidate Shown to Neutralize Omicron Variant
  • [H3] Bhlhe40, a molecular gatekeeper that prevents the formation of lymphomas
  • [H3] Valneva Confirms Clinical Trial and Regulatory Submission Timelines for its Inactivated COVID-19 Vaccine Candidate VLA2001
  • [H3] Tim Clausen and collaborators secure two prestigious grants
  • [H3] CEBINA reports broad anti-viral potency of azelastine has potential for use against influenza and RSV infections in addition to SARS-CoV-2 and its variants of concern including the Omicron variant
  • [H3] Anna Obenauf and Clemens Plaschka elected EMBO Young Investigators
  • [H3] Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy
  • [H3] PhagoMed becomes BioNTech R&D (Austria)
  • [H3] Breakthrough research on human blastoids and impact on IVF and contraception
  • [H3] Valneva Confirms Initiation of Rolling Review with EMA and Provides Updates on its COVID-19 Vaccine Program VLA2001
  • [H3] Valneva and IDT Biologika Announce Collaboration for Production of Inactivated COVID-19 Vaccine VLA2001
  • [H3] Prestigious prize of the Austrian Society of Allergology and Immunology for Louisa Hill
  • [H3] Anete Romanauska wins Science & SciLifeLab Prize
  • [H3] CRY2, a component of the bird internal clock
  • [H3] Valneva Signs Purchase Agreement with European Commission for its Inactivated COVID-19 Vaccine VLA2001
  • [H3] ‘Network medicine’ directs disease diagnosis
  • [H3] Melanie de Almeida wins the Lauwers Award
  • [H3] Decoding the role of PHF3 in transcription
  • [H3] Vienna BioCenter PhD Awards 2021 for two IMP and two IMBA graduates
  • [H3] How cells keep their nucleus clean: a fundamental discovery
  • [H3] Ares Genetics launches AREScloud for the analysis of sequenced clinical isolates
  • [H3] FWF grants awarded to Max Perutz Labs researchers
  • [H3] Prestigious grants for Rushad Pavri and Wouter Masselink
  • [H3] Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
  • [H3] miR-1: an ancient molecule controls muscle physiology
  • [H3] Louisa Hill wins the Rabitsch Award 2021
  • [H3] Mission possible: how cohesin fits two meters of DNA into a human cell
  • [H3] International Birnstiel Award 2021 for six outstanding young scientists
  • [H3] “Always try to disprove your results”
  • [H3] Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate
  • [H3] How to detox the nucleus of unsaturated fat
  • [H3] Valneva Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivated COVID-19 Vaccine
  • [H3] “This is one of the best times to do science”
  • [H3] Federal Minister of Health Wolfgang Mückstein visits Vienna BioCenter
  • [H3] Close friends and distant relatives
  • [H3] Valneva Commences Rolling Submission to MHRA for its Inactivated, Adjuvanted COVID-19 Vaccine
  • [H3] Vienna BioCenter Summer School welcomes 15 students from around the world
  • [H3] PETISCO - a multi-tool for piRNA processing
  • [H3] Proteus changes his Akt
  • [H3] Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate
  • [H3] "Tardigrades take the stage" - Adrià Nogales Moral about his research topic and scientific outreach
  • [H3] Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate
  • [H3] Vienna BioCenter researchers hone method for low-cost mass analysis of SARS-CoV-2 mutations
  • [H3] The Embassy of the State of Israel visits the Vienna BioCenter
  • [H3] An internship program for Salvadoran students at the IMP
  • [H3] Signal transduction: In the right place, at the right time
  • [H3] Cross-resistance: when cancer therapy backfires
  • [H3] Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate
  • [H3] Boehringer Ingelheim awards the Grass Roots Innovation Prize to a:head bio AG
  • [H3] Valneva to Host Symposium on COVID-19 and Chikungunya Vaccine Candidates at 31st European Congress of Clinical Microbiology & Infectious Diseases
  • [H3] Hitting the right note in dialysis care
  • [H3] Max Perutz PhD Fellowships
  • [H3] Profiling gene expression in plant embryos one nucleus at a time
  • [H3] Hot off the press: a new role for histone modifications in genomic imprinting
  • [H3] ÖAW DOC Fellowships for Max Perutz Labs students
  • [H3] CEBINA announces the launch of Danube Labs
  • [H3] Amygdala: a piece in the puzzle of pain
  • [H3] Valneva Completes Recruitment for Phase 3 Lot-to-Lot Consistency Trial of its Chikungunya Vaccine Candidate
  • [H3] Meiosis: Mind the gap
  • [H3] Disrupting ribosome production – renewed potential for cancer therapy
  • [H3] Two Max Perutz Labs scientists elected as EMBO members
  • [H3] Valneva Completes Phase 3 Trial Recruitment for its Inactivated COVID-19 Vaccine Candidate
  • [H3] Colouring tumours reveals their bad influence
  • [H3] Building muscles from liquids – phase separation in the Z-disc
  • [H3] Biology in the holodeck: exploring cellular interactions with virtual reality
  • [H3] Harnessing Next Generation Sequencing to detect SARS-CoV-2 and prepare for the next pandemic
  • [H3] Valneva to Participate in the World’s First COVID-19 Vaccine Booster Trial in the UK
  • [H3] IMP scientists put limb regeneration under the lens
  • [H3] International Birnstiel Award opens 2021 call
  • [H3] Anete Romanauska receives Denise P. Barlow Award
  • [H3] Valneva Announces the Pricing of its Initial Public Offering on Nasdaq
  • [H3] A protein bodyguard – private security in the defense against oxidation
  • [H3] Two ERC Advanced Grants for research at Vienna BioCenter
  • [H3] Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
  • [H3] Keeping oocytes fit with Topoisomerase-3
  • [H3] Flowering rooted in embryonic gene-regulation
  • [H3] From Bench to Bedside - Molecular Pathogenesis to Precision Medicine
  • [H3] Valneva Completes Recruitment for Pivotal Phase 3 Trial of Chikungunya Vaccine Candidate and Initiates Antibody Persistence Trial
  • [H3] Brain organoids uncover various mechanisms of virus-induced microcephaly
  • [H3] Lockdown for genome parasites
  • [H3] Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
  • [H3] No centrioles? No problem!
  • [H3] Tiny droplets – huge impact: FWF doc.funds grant on liquid-liquid phase separation
  • [H3] Hidden in plain sight: A-type lamins in the nucleus
  • [H3] When synthetic evolution rhymes with natural diversity
  • [H3] Living in a gated community – how stem cells preserve their identity
  • [H3] Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate
  • [H3] Valneva Reports FY 2020 Results and Major Corporate Achievements
  • [H3] Valneva Initiates Phase 3 Clinical Lot Consistency Study for its Single-Shot Chikungunya Vaccine Candidate
  • [H3] Tearing down walls for a new beginning
  • [H3] Silencing by crosstalk
  • [H3] Shedding new light on an old problem
  • [H3] “Basic research and teaching should go hand-in-hand”
  • [H3] Valneva Announces UK Government Exercise of Option for 40 Million Doses of its Inactivated, Adjuvanted COVID-19 Vaccine
  • [H3] Valneva Commences Manufacturing of its Inactivated, Adjuvanted COVID-19 Vaccine, Completes Phase 1/2 Study Recruitment
  • [H3] Biolution proudly presents its new demo reel
  • [H3] Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income Countries
  • [H3] Strength in numbers: how weak enhancers can be powerful gene regulators
  • [H3] Revealing the genetic code of ribosomal RNAs
  • [H3] Valneva in Advanced Discussions with European Commission to Supply up to 60 Million Doses of Inactivated, Adjuvanted COVID-19 Vaccine Candidate
  • [H3] More than just a sun tan: ultraviolet light helps marine animals to tell the time of year
  • [H3] Valneva Strengthens Management Team; Appoints Perry Celentano as Interim COO and David Lawrence as Acting CFO
  • [H3] Selfish elements turn embryos into a battlefield
  • [H3] Valneva Reports FY 2020 Cash of Over €200 Million
  • [H3] SMICH Doctoral Program receives funding by FWF
  • [H3] Valneva Initiates Phase 1/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine Candidate
  • [H3] IMBA Group Leader Nicolas Rivron secures prestigious ERC Grant
  • [H3] Exploring the molecular basis of heredity: ERC grant for Joao Matos
  • [H3] Leading supercomputer cluster starts operations at Vienna BioCenter
  • [H3] Valneva Announces Plans for Extraordinary General Meeting to Prepare for Potential US IPO
  • [H3] The testing technology of the future: 36,000 samples in one night
  • [H3] Valneva Reports Nine Month Results Marked by Further Major Corporate Achievements
  • [H3] A groundbreaking genetic screening tool for human organoids
  • [H3] PCR alternative: RT-LAMP, a new SARS-CoV-2 test "Made in Vienna"
  • [H3] Valneva’s Chikungunya Vaccine Candidate Awarded EMA Prime Designation
  • [H3] “No service!” How vaccinia virus jams immune signaling
  • [H3] Congratulations to Emmanuelle Charpentier on the Nobel Prize for Chemistry
  • [H3] OpGen Group Company Ares Genetics Wins Austrian Digitization Award for ares-genetics.cloud
  • [H3] What is the origin of the genetic code?
  • [H3] Unraveling the genome in 3D-space
  • [H3] Vienna Covid-19 Detection Initiative (VCDI): a response to Covid-19 from the Vienna BioCenter
  • [H3] Valneva Announces Retirement of Chief Financial Officer David Lawrence
  • [H3] Investigating Parkinson’s through the lens of autophagy - ASAP grant for Sascha Martens
  • [H3] The Wnt pathway gets even more complicated
  • [H3] Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government
  • [H3] City of Vienna honours Meinrad Busslinger
  • [H3] Valneva Announces New IXIARO® Supply Contract with the US Government worth up to $166 million
  • [H3] Valneva Initiates Phase 3 Clinical Study for its Chikungunya Vaccine Candidate VLA1553
  • [H3] IMBA is lead participant in a new, cell-based medicine initiative for Europe
  • [H3] Evomet – a project to train future leaders in metastasis research
  • [H3] Autophagy: the beginning of the end
  • [H3] ERC Starting Grant awarded to Clemens Plaschka of IMP
  • [H3] Cell division: cleaning the nucleus without detergents
  • [H3] Calcium causes stiff joints in ɑ-actinin
  • [H3] A step towards understanding how animals detect the Earth's magentic field
  • [H3] Valneva Reports H1 Results Marked by Major Corporate Achievements and Strong Cash Position
  • [H3] Detective work in the cell: Scientists uncover a new RNA-modifying enzyme
  • [H3] Startup Labs at the Vienna BioCenter open their doors 
  • [H3] CaTCH - a molecular time machine for cells
  • [H3] Cancer research: Vienna BioCenter start-up breaks new ground in drug discovery
  • [H3] Sascha Martens elected EMBO member: “I’m looking forward to helping support young scientists”
  • [H3] How the immune system generates a vast antibody repertoire to fight infections
  • [H3] Cep97: a stabilizing protein roof for centrioles
  • [H3] Researchers develop a "quick and easy" Covid-19 test for population screening with simple means
  • [H3] Valneva and Bavarian Nordic Announce Marketing and Distribution Partnership
  • [H3] Batavia Biosciences and Valneva Collaborate to Accelerate Development of Low-cost Inactivated Polio Vaccine
  • [H3] Valneva announces HSR clearance for Lyme vaccine collaboration with Pfizer
  • [H3] Valneva Announces Publication in The Lancet of Complete Phase 1 Data for its Single-Shot Chikungunya Vaccine Candidate
  • [H3] A “DEEP-Clear” view of nervous system diversity
  • [H3] Happy - virtual - birthday, Max Perutz!
  • [H3] Jürgen Knoblich now in ISSCR Board of Directors
  • [H3] “Reverse engineering” autophagosome biogenesis reveals new protein interactions
  • [H3] Scientists discover a gene to stay thin
  • [H3] IMP & Birnstiel Foundation open call for 2020 Birnstiel Award
  • [H3] How plants forget - new work uncovers how epigenetic marks are specifically reset in sperm
  • [H3] Valneva Reports Q1 Results and Updates 2020 Guidance Following Major Lyme Partnering Deal
  • [H3] Valneva to Partner with Instituto Butantan on Single-Shot Chikungunya Vaccine for Low- and Middle- Income Countries
  • [H3] Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15
  • [H3] Valneva and Dynavax Announce Collaboration to Advance Vaccine Development for COVID-19
  • [H3] CEBINA joins the global efforts to fight COVID-19
  • [H3] Fighting SARS-CoV-2 in human blood vessel organoids
  • [H3] Alwin Köhler appointed as Scientific Director
  • [H3] Valneva Reports Positive End-of-Phase 2 Chikungunya Meeting with the U.S. FDA; Sets Stage for Phase 3 Study
  • [H3] Valneva Provides Business Update on COVID-19 Situation
  • [H3] Layered Liquids – reaction chambers for gene regulation
  • [H3] Valneva Announces FDA Approval of IXIARO® Shelf Life Extension to 36 Months; New US Military RFP Issued
  • [H3] 7th Ubiquitin Symposium at the Vienna BioCenter
  • [H3] CALYXHA endeavors to develop novel approaches to tissue degenerative diseases and receives support from Austrian VC and international investors
  • [H3] Mechanism of inactivation of the tumor suppressor PP2A: an illusion shattered by reality
  • [H3] VBC PhD student Anete Romanauska wins Harold M. Weintraub Graduate Student Award
  • [H3] Valneva Reports Record Product Sales and Major Pipeline Progress in 2019
  • [H3] Fungal pathogens tap human iron stores to survive immunity
  • [H3] How bacteria sense and adjust cell envelope precursors
  • [H3] FEBS | EMBO Women in Science Award 2020 for IMP's Elly Tanaka
  • [H3] Aelian Wins Vienna 5G Use Case Challenge
  • [H3] ToxPHACTS available for purchase
  • [H3] Valneva Announces New $85 Million Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed
  • [H3] Curetis Company Ares Genetics and BGI Group to Offer Sequencing and PCRbased Coronavirus (2019-nCoV) Testing in Europe
  • [H3] Calibrating the tools of life scientists: Antibodies
  • [H3] AFFiRiS announces Phase 2 study in Parkinson's and new focus on neurodegenerative diseases
  • [H3] Phenaris launches Transporter Models
  • [H3] How decisions unfold in a zebrafish brain
  • [H3] Valneva: US DoD Exercises Option on IXIARO® Supply Contract Bringing Total Value to $70 Million
  • [H3] Valneva Expands its Commercial Operations with the Opening of its French Commercial Office
  • [H3] Valneva Announces End of Phase 2 Meeting with the FDA for its Chikungunya Vaccine Candidate
  • [H3] Valneva Completes Delisting from the Vienna Stock Exchange
  • [H3] Moonstruck worms: how lunar cycles affect metabolic decisions
  • [H3] Valneva Appoints MVM Partner Thomas Casdagli to its Supervisory Board
  • [H3] “ERC-Hattrick” for IMBA Group leader Stefan Ameres
  • [H3] Valneva Appoints Renowned Vaccinologists Stanley Plotkin and Anna Durbin to its Scientific Advisory Board
  • [H3] Valneva to Conduct Investor and Partnering Meetings during the 38th Annual J.P. Morgan Healthcare Conference
  • [H3] Three Special Research Programme grants for Vienna BioCenter scientists
  • [H3] A large-scale public event bridging science and society
  • [H3] Putting a Lid on Multidrug Resistance
  • [H3] Valneva Announces EMA Approval of IXIARO® Shelf Life Extension to 36 Months
  • [H3] Harnessing the power of CRISPR in space and time
  • [H3] Curetis Group Company Ares Genetics Wins MERCUR Innovation Prize
  • [H3] IMP researchers show that cohesin is a "molecular machine"
  • [H3] Valneva Reports Excellent Final Phase 1 Results for its Chikungunya Vaccine Candidate, Confirms Plans
  • [H3] Valneva Announces Appointments of Two Leading Vaccine Experts to its Scientific Advisory Board
  • [H3] Vienna BioCenter PhD Awards 2019
  • [H3] Eveliqure's effort to develop a Shigella-ETEC combination vaccine for travelers and children in resource poor countries is supported by the Wellcome Trust
  • [H3] Limits vs. chances of Biotechnology: A public debate
  • [H3] Valneva Raises Product Sales Guidance Following Strong Nine-Month Results and R&D Execution
  • [H3] Ares Genetics Launches AI-powered Molecular Antibiotic Susceptibility Test
  • [H3] Essential biochemical process driven by alternative cellular fuel discovered
  • [H3] a:head signs license and collaboration agreements with IMBA and awarded funding from FFG
  • [H3] FOR WOMEN IN SCIENCE - IMBA PhD student receives L'Oréal fellowship
  • [H3] Eveliqure's diarrhoea vaccine to advance towards clinical trials supported by significant Horizon2020 award.
  • [H3] PhagoMed Accelerates R&D Program Against Bacterial Vaginosis. Phage Lysin Stabilizes Vaginal Microbiome.
  • [H3] Four PhD fellowships for Max Perutz Labs students
  • [H3] VBC postdoc symposium on publishing models
  • [H3] IMP scientists discover a mechanism that controls autoimmunity
  • [H3] Anete Romanauska is Researcher of the Month at the Medical University of Vienna
  • [H3] It takes two to tango: using the ubiquitin fold to turn on secretion
  • [H3] Novel Catalase for complete neutralization of H2O2 in agar plates
  • [H3] Valneva Confirms Delisting from the Vienna Stock Exchange
  • [H3] IMP and Birnstiel Foundation honour three young scientists with research award
  • [H3] Campus Open Day: 11 October 2019
  • [H3] ERC funds to help predict drug responses
  • [H3] ERC grant for incoming IMP scientist Francisco Balzarotti
  • [H3] Why are small RNA so important?
  • [H3] Fighting genomic parasites – lessons from an unusual organism
  • [H3] Valneva Announces Management Board Stock Purchases
  • [H3] Ares Genetics Launches Service Laboratory for NGS-based Molecular Drug Resistance Testing
  • [H3] Keeping the genome in shape: a physiological role for NHEJ in meiosis
  • [H3] Upcycling of proteins protects DNA from parasites
  • [H3] a:head - launched to transform CNS drug discovery
  • [H3] "Science is my life" - Interview with Professor Hans Tuppy
  • [H3] Valneva Reports H1 2019 Results Marked by Strong Operational Performance and Major Corporate Progress
  • [H3] Valneva Announces Formation of Scientific Advisory Board
  • [H3] CEPI awards up to US$23.4 million to Valneva for late-stage development of a single-dose Chikungunya vaccine
  • [H3] How does a neural stem cell know its age?
  • [H3] Valneva Announces Drawdown of Further €10 million from its Existing European Investment Bank Loan
  • [H3] HOOKIPA Announces FDA Clearance of IND Application for HB-201 Clinical Trial to Treat HPV-Positive Cancers
  • [H3] Centrioles - critical players in cell division
  • [H3] Ares Genetics is granted key European patent on genetic resistance testing
  • [H3] Valneva: Renowned Vaccinologist Dr. Stanley Plotkin to Present at R&D Investor Day in New York City on July 9th
  • [H3] How cells quickly activate innate immunity
  • [H3] SCARLETRED: Patents granted in Japan and Australia
  • [H3] Valneva Submits Delisting Application to the Vienna Stock Exchange
  • [H3] Valneva Initiates Second Phase 2 Study for its Lyme Disease Vaccine Candidate VLA15
  • [H3] PhagoMed Biopharma GmbH successfully completed another financing round.
  • [H3] Valneva Shareholders Approve all Resolutions Recommended by the Management Board at the Annual General Meeting
  • [H3] Valneva Announces Mutual Agreement with GSK to End Strategic Alliance Agreement; Regains Control of R&D
  • [H3] New tool for visualizing molecule properties developed at the Max Perutz Labs
  • [H3] “I am excited by the idea that we discover the unknown about the most fundamental things in life.”
  • [H3] Valneva to Present Lyme Disease and Chikungunya Vaccine Updates at R&D Investor Day in New York City on July 9th
  • [H3] Valneva Reports Successful Outcome of Phase 2 Run-In for its Lyme Disease Vaccine Candidate
  • [H3] HOOKIPA Pharma Announces Oral Presentation of HB-101 CMV Vaccine Phase 1 Data at the American Transplant Congress
  • [H3] Vienna BioCenter hosts first EMBO Fellow Mini-Symposium
  • [H3] First Max Perutz Day kicks off a new era at the Max Perutz Labs Vienna
  • [H3] EMBO workshop at the Vienna BioCenter in September to discuss genome organisation by SMC complexes
  • [H3] New video tutorial on how to use SLAMseq for profiling transcriptional responses to drugs
  • [H3] Phages take center stage in a new animation by biolution
  • [H3] An amplified spindle
  • [H3] Valneva Reports Further Positive Results for Its Chikungunya Vaccine Candidate
  • [H3] First EMBO Fellow symposium at Vienna BioCenter
  • [H3] Audio portray on David Haselbach's work on molecular machines
  • [H3] Activation of gene promoters: Vienna BioCenter scientists discover basis of regulatory specificity
  • [H3] HOOKIPA Achieves Research Milestone in HBV Collaboration and License Agreement with Gilead
  • [H3] Valneva Reports Strong Q1 2019 Operating Results and Advances Key R&D Programs towards Major Milestones
  • [H3] Birnstiel Award: international competition of best PhD students
  • [H3] Vienna BioCenter launches "VIP2": a three-year postdoctoral program.
  • [H3] Arabidopsis immune system is triggered by small bacterial fatty acids
  • [H3] Andreas Bachmair appointed full professor
  • [H3] Valneva to Present on Lyme and Chikungunya Vaccine Candidates at the 19th World Vaccine Congress
  • [H3] A new type of protein phosphorylation characterised
  • [H3] New funding for stem cell research at MFPL and the Vienna BioCenter
  • [H3] Student Open Day
  • [H3] VBC PhD Programme: Open Call until 15 April 2019
  • [H3] Four new Marie Curie Fellowships at the Vienna BioCenter
  • [H3] HOOKIPA Pharma Raises $37.4 million (€33.2 million) in Series D Financing
  • [H3] New animation video explains gene expression in unprecedented detail
  • [H3] Valneva Reports Strong 2018 Results, Expects Further Growth and Major Pipeline Progression in 2019
  • [H3] Ares Genetics and QIAGEN Enter into Bioinformatics Partnership to Fight Antimicrobial Resistance
  • [H3] SY-Stem Symposium at the Vienna BioCenter: 21-23 March 2019.
  • [H3] 14th Microsymposium on Small RNA Biology at the Vienna BioCenter: 15-17 May 2019.
  • [H3] HOOKIPA Appoints Michael A. Kelly as Independent Director
  • [H3] Ubiquitin & Friends 2019: symposium in Vienna
  • [H3] Audio portrait of IMP Group Leader Clemens Plaschka
  • [H3] Valneva Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate
  • [H3] Vienna BioCenter at the ball of sciences
  • [H3] 10 Million Euros for Access to European Proteomics Facilities
  • [H3] Obituary: Andreas Weith (1953 to 2019), former IMP Group Leader
  • [H3] Valneva Announces New $59 Million IXIARO® Supply Contract with US Government
  • [H3] Valneva Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019
  • [H3] Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate
  • [H3] Ares Genetics Advances AI-powered Infectious Disease and Antibiotic Resistance Test
  • [H3] Valneva Announces its Intention to Delist from the Vienna Stock Exchange
  • [H3] HOOKIPA Achieves First Research Milestone in HIV Collaboration and License Agreement with Gilead
  • [H3] Valneva Awarded FDA Fast Track Designation for Chikungunya Vaccine Candidate
  • [H3] VBC Summer School 2019 application deadline: 31 January 2019
  • [H3] Ares Genetics Teams Up with Leading Global Pharma Company in Fight Against Antibiotic Resistance
  • [H3] Valneva Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate
  • [H3] HOOKIPA Doses First Patient in a Phase 2 Clinical Trial of Prophylactic Vaccine Candidate HB-101 against Cytomegalovirus
  • [H3] VIENNA BIOCENTER CORE FACILITIES
  • [H3] Analysis / statistics

Bilder

Es konnten 673 Bilder auf dieser Webseite gefunden werden.

Auf vbc.ac.at fehlen bei 599 von 673 Bilddateien ALT-Attribute. Beschreibende Alternativtexte helfen Suchmaschinen und verbessern zugleich die Zugänglichkeit der Seite.

Text/HTML Verhältnis

Anteil : 8%

vbc.ac.at hat mit 8% einen sehr niedrigen Textanteil. Die Seite sollte mehr nutzbaren Inhalt erhalten, damit Suchmaschinen nicht nur Code, Navigation oder Gestaltungselemente sehen.

Flash

vbc.ac.at verzichtet auf Flash-Inhalte. Dadurch bleibt die Seite technisch zeitgemäßer und für Nutzer wie Suchmaschinen leichter zugänglich.

IFrame

vbc.ac.at nutzt IFrames. Prüfen Sie, ob wichtige Inhalte direkt auf der Seite ausgegeben werden können, damit sie besser indexierbar und unabhängiger von externen Quellen sind.

Eine klare Linkstruktur erleichtert Suchmaschinen das Crawlen, verteilt interne Relevanz und hilft Besuchern, wichtige Inhalte schnell zu finden.

URL Rewrite

Die URLs von vbc.ac.at sind gut lesbar und wirken suchmaschinenfreundlich. Sprechende Links helfen Nutzern und Crawlern, den Inhalt einer Seite bereits anhand der Adresse besser einzuschätzen.

Underscores in the URLs

vbc.ac.at verwendet keine Unterstriche in den geprüften Links. Das unterstützt eine klare und übliche URL-Schreibweise.

In-page links

We found a total of 93 links including 0 link(s) to files

Anker Typ Natürlich
Apply intern natürliche Links
Contact intern natürliche Links
Research at Vienna BioCenter intern natürliche Links
Research Entities intern natürliche Links
Research Areas intern natürliche Links
Anthropogenic Evolution intern natürliche Links
Biochemistry, Biophysics, Structure intern natürliche Links
Cell and Chromosome Biology intern natürliche Links
Cognitive and Behavioral Biology intern natürliche Links
Computational Biology, Genomes and Evolution intern natürliche Links
Disease Mechanisms, Immunology, Pathogens intern natürliche Links
Gene Regulation, RNA, Epigenetics intern natürliche Links
Microbiology and Environmental Systems Science intern natürliche Links
Neurobiology intern natürliche Links
Plant Sciences intern natürliche Links
Stem Cells, Development, Regeneration intern natürliche Links
Research Groups intern natürliche Links
Key Discoveries intern natürliche Links
CRISPR/Cas9 intern natürliche Links
MECHANISMS OF CHROMOSOME SEGREGATION intern natürliche Links
HUMAN BRAIN ORGANOIDS intern natürliche Links
EPIGENETICS intern natürliche Links
1001 GENOMES intern natürliche Links
Recent Research Highlights intern natürliche Links
VBCF Landing Page intern natürliche Links
Child Care Center intern natürliche Links
Companies at Vienna BioCenter intern natürliche Links
Biotech Companies intern natürliche Links
Alpine Engineering intern natürliche Links
a:head intern natürliche Links
Ablevia biotech intern natürliche Links
ADvantage Therapeutics intern natürliche Links
aitiologic GmbH intern natürliche Links
Akribes intern natürliche Links
Austrianni intern natürliche Links
BioNTech R&D Austria intern natürliche Links
Biosynth intern natürliche Links
bit.bio discovery GmbH intern natürliche Links
CALYXHA Biotechnologies intern natürliche Links
ChanPharm intern natürliche Links
dawn bio intern natürliche Links
Elaris intern natürliche Links
Epitome Therapeutics intern natürliche Links
Eveliqure intern natürliche Links
Fragrami intern natürliche Links
HeartBeat.bio AG intern natürliche Links
HOOKIPA Pharma Inc. intern natürliche Links
JLP Health intern natürliche Links
Lexogen intern natürliche Links
Miti Biosystems intern natürliche Links
Mobius Biotechnology intern natürliche Links
MyeloPro Diagnostics and Research GmbH intern natürliche Links
Myllia Biotechnology intern natürliche Links
OncoOne intern natürliche Links
Parallel Bio intern natürliche Links
proxygen GmbH intern natürliche Links
QUANTRO Therapeutics intern natürliche Links
SCARLETRED intern natürliche Links
Thermo Fisher Scientific intern natürliche Links
THT Biomaterials GmbH intern natürliche Links
Tridem Bioscience intern natürliche Links
Valneva intern natürliche Links
ViroTrust Diagnostics intern natürliche Links
Viverita Discovery intern natürliche Links
X4 Pharmaceuticals intern natürliche Links
YGION Biomedical GmbH intern natürliche Links
Service Companies intern natürliche Links
biolution intern natürliche Links
LabShop at Vienna BioCenter directed by LabConsulting GmbH & LC LabService GmbH intern natürliche Links
net4biz intern natürliche Links
IG StartUP Solutions GmbH intern natürliche Links
Business Incubators intern natürliche Links
CEBINA intern natürliche Links
INiTS intern natürliche Links
Welcome Office intern natürliche Links
Why Work Here intern natürliche Links
Campus Life intern natürliche Links
Life in Vienna intern natürliche Links
About Vienna BioCenter intern natürliche Links
Virtual Tour intern natürliche Links
News intern natürliche Links
Events at the Vienna BioCenter intern natürliche Links
Sustainability intern natürliche Links
Downloads intern natürliche Links
GMI intern natürliche Links
IMBA intern natürliche Links
IMP intern natürliche Links
Max Perutz Labs intern natürliche Links
CeMESS intern natürliche Links
Faculty of Life Sciences intern natürliche Links
basic research in plants extern natürliche Links
key discoveries extern natürliche Links
Legal Notice & Imprint intern natürliche Links

SEO Suchbegriffe

Die Suchbegriffsauswertung zeigt, welche Themen die Seite tatsächlich vermittelt und ob wichtige Begriffe in Inhalt und Seitenelementen konsistent vorkommen.

Suchbegriffswolke

research imp new how vaccine biocenter valneva candidate vienna back

Keywords Consistency

Suchbegriff Inhalt Seitentitel Suchbegriffe Seitenbeschreibung Überschriften
valneva 49
vaccine 37
vienna 33
new 24
biocenter 23

Benutzerfreundlichkeit

Gute Benutzerfreundlichkeit stärkt Vertrauen und erleichtert die Nutzung. Geprüft werden unter anderem URL, Favicon, Sprache und Druckdarstellung.

URL

Domain : vbc.ac.at

Länge : 9

Favoriten Icon

vbc.ac.at stellt ein Favicon bereit. Dieses kleine Symbol verbessert Wiedererkennung in Browser-Tabs, Lesezeichen und Suchergebnisumgebungen.

Druckeigenschaften

vbc.ac.at hat offenbar keine druckfreundliche CSS-Variante. Wenn Inhalte häufig ausgedruckt werden, lohnt sich eine angepasste Print-Darstellung.

Sprache

Die Spracheinstellung von vbc.ac.at ist vorhanden: en. Diese Angabe macht das Dokument für Crawler und assistive Technologien klarer interpretierbar.

Dublin Core

Bei vbc.ac.at wurden keine Dublin-Core-Elemente gefunden. Das ist nicht für jede Website zwingend, kann aber bei dokumentenartigen oder redaktionellen Inhalten nützlich sein.

Dokument

Sauberes HTML, eine korrekte Zeichencodierung und moderne Standards verbessern Kompatibilität, Zugänglichkeit und die zuverlässige Verarbeitung der Seite.

Doctype

HTML 5

Verschlüsselung

vbc.ac.at deklariert den Zeichensatz UTF-8. Das ist wichtig, damit Sonderzeichen, Umlaute und typografische Zeichen korrekt dargestellt werden.

W3C Validität

Fehler : 0

Warnungen : 0

E-Mail Datenschutz

vbc.ac.at zeigt keine offen auslesbare E-Mail-Adresse. Das ist positiv für Datenschutz und Spam-Vermeidung.

Veraltetes HTML

Im Quelltext von vbc.ac.at wurden keine deprecated HTML-Tags erkannt. Aktuelle HTML-Strukturen sind robuster für Browser und Validatoren.

Tipps zur Webseitengeschwindigkeit

vbc.ac.at nutzt keine verschachtelten Tabellen. Das macht Layout und Quelltext leichter wartbar und besser zugänglich.
Auf vbc.ac.at wurden Inline-CSS-Angaben gefunden. Wenn möglich, sollten diese Regeln in Stylesheets verlagert werden, damit Gestaltung und Inhalt sauberer getrennt sind.
vbc.ac.at verwendet mit 1 CSS-Dateien eine überschaubare Stylesheet-Struktur. Das kann Ladezeit und Wartung positiv beeinflussen.
vbc.ac.at bindet mit 5 JavaScript-Dateien nur eine begrenzte Menge Skripte ein. Das ist eine gute Grundlage für schnelle Ladezeiten.
vbc.ac.at nutzt gzip-Komprimierung. Dadurch können HTML, CSS und JavaScript kleiner übertragen werden, was die Ladezeit verbessern kann.

Mobile

Mobile Optimierung ist wichtig, weil viele Besucher Smartphones nutzen. Viewport, Icons und ungeeignete Technologien beeinflussen Darstellung und Bedienbarkeit.

Mobile Optimierung

Apple Icon
META Viewport Tag
Flash Inhalt

Optimierung

Sitemap, robots.txt, Komprimierung und Analysesysteme beeinflussen, wie effizient eine Website gecrawlt, ausgeliefert und gezielt weiterentwickelt werden kann.

XML-Sitemap

Eine XML-Sitemap ist für vbc.ac.at vorhanden. Sie unterstützt Crawler dabei, die Seitenstruktur effizienter zu verstehen.

https://www.viennabiocenter.org/sitemap.xml

Robots.txt

http://vbc.ac.at/robots.txt

Eine robots.txt ist für vbc.ac.at vorhanden. Das ist die richtige Stelle, um Suchmaschinen den Umgang mit bestimmten Bereichen der Website zu erklären.

Analytics

Ein Analytics-System ist bei vbc.ac.at vorhanden. Das ermöglicht eine bessere Bewertung von Traffic, Verhalten und Verbesserungsbedarf.

   Google Analytics

PageSpeed Insights

PageSpeed Insights bewertet Leistung, Barrierefreiheit, bewährte Verfahren und SEO für Desktop und Mobilgeräte und macht technische Bremsen sichtbar.

Gerät
Kategorien

Website-Überprüfung

Website-Überprüfung ist ein kostenloses SEO Werkzeug zur Analyse Ihrer Webseite